IDiyas

For the Inventor, By the Inventor

La Chaux-de-Fonds, Switzerland

Glenmark Pharmaceuticals S.a.


USPTO Granted Patents = 64



Trademarks = 1

Forward Citations = 306

Loading Chart...
Loading Chart...

100 inventors (with patents filed for the assignee):

goldMedal Neelima Khairatkar-Joshi (33 out of 44 patents)

silverMedal Abraham Thomas (30 out of 31 patents)

bronzeMedal Laxmikant Atmaram Gharat (22 out of 24 patents)

4.  Vidya Ganapati Kattige (13 out of 14 patents)

5.  Sukeerthi Kumar (12 out of 12 patents)

6.  Daisy Manish Shah (11 out of 12 patents)

7.  Indranil Mukhopadhyay (11 out of 11 patents)

8.  Sachin Sundarlal Chaudhari (11 out of 11 patents)

9.  Suresh Mahadev Kadam (8 out of 14 patents)

10.  Stanislas Blein (7 out of 15 patents)

11.  Malini Bajpai (7 out of 7 patents)

12.  Nagarajan Muthukaman (7 out of 8 patents)

13.  Balasubramanian Gopalan (7 out of 8 patents)

14.  Sanjib Das (6 out of 6 patents)

15.  Shailesh Ramesh Pardeshi (6 out of 6 patents)


Core Competencies:
ROR Gamma Modulators
TRPA1 Antagonists
mPGES-1 Inhibitors
Hetero-Dimeric Immunoglobulins
Bicyclic Compounds
Thienopyrimidinedione Derivatives
Antibodies Binding to TL1A
Respiratory Disorder Treatments
Dipeptidyl Peptidase-IV Inhibitors
Cannabinoid Receptor Ligands
Fused Pyrimidine Derivatives
Chromane Derivatives

64 patents:

1. 10988467 - Compounds as ROR gamma modulators (2021-04-27),
2. 10603277 - Nanoparticulate formulation comprising a TRPA1 antagonist (2020-03-31),
3. 10457649 - Polymorphs of a mPGES-1 inhibiting triazolone compound (2019-10-29),
4. 10391083 - Triazolone compounds as MPGES-1 inhibitors (2019-08-27),
5. 10344024 - Compounds as ROR gamma modulators (2019-07-09),
6. 10336688 - Carbocyclic compounds as ROR gamma modulators (2019-07-02),
7. 10213558 - Drug delivery device (2019-02-26),
8. 10189775 - Carbocyclic compounds as ROR gamma modulators (2019-01-29),
9. 10112914 - Polymorphs of a mPGES-1 inhibiting triazolone compound (2018-10-30),
10. D823460 - Anal device (2018-07-17),
11. 9975887 - Compounds as ROR gamma modulators (2018-05-22),
12. 9949955 - Triazolone compounds as mPGES-1 inhibitors (2018-04-24),
13. 9855229 - Treatment of respiratory disorders using ROR-gamma inhibitors (2018-01-02),
14. 9718817 - Aryl and heteroaryl ether compounds as ROR gamma modulators (2017-08-01),
15. 9683053 - Hetero-dimeric immunoglobulins (2017-06-20),
Glenmark Pharmaceuticals S.A. is a global pharmaceutical company headquartered in Mumbai, India. With a presence in over 80 countries, Glenmark focuses on the development, manufacturing, and marketing of high-quality generic and branded pharmaceutical products. The company's diverse product portfolio includes medications for cardiovascular diseases, respiratory disorders, dermatology, oncology, and more. Glenmark's commitment to innovation and research has led to several breakthrough medications and has earned them recognition in the industry. They strive to improve the health and well-being of people worldwide through their affordable and accessible medicines.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

...
64 Patents

#2 in La Chaux-de-Fonds

#222 in Switzerland

#11,001 in the World

...
La Chaux-de-Fonds, Switzerland

Glenmark Pharmaceuticals S.a.

Forward Citations = 306

100 inventors:

goldMedal Neelima Khairatkar-Joshi (33 out of 44 patents)

silverMedal Abraham Thomas (30 out of 31 patents)

bronzeMedal Laxmikant Atmaram Gharat (22 out of 24 patents)

4.  Vidya Ganapati Kattige (13 out of 14 patents)

5.  Sukeerthi Kumar (12 out of 12 patents)

Please report any incorrect information to support@idiyas.com
Loading…